InterVenn Biosciences
AI-Based Cancer Detection

Protein glycosylation is a fundamental process in nature that controls essential biological pathways, ranging from protein trafficking and cell adhesion to host-pathogen interactions. The diverse and complex structure of glycans on proteins often directs specific biological processes and, when altered, can give rise to various diseases. Therefore, understanding the basic principles of protein glycosylation is vital to medical science. Glycoproteomics is an essential yet highly complex field of study that can immensely enhance the early detection, diagnostics, treatment selection, and monitoring processes for various cancers and even other diseases.


The need for more informative biomarkers and deeper insights into the nature of most diseases has become increasingly apparent. InterVenn, a biotech startup, addresses this need with a powerful new biomarker discovery platform that interrogates the glycoproteome as a previously unexplored yet ubiquitously important aspect of biology. Utilizing AI, InterVenn Biosciences has developed a first-of-its-kind glycoproteomics-based liquid biopsy solution to detect and diagnose cancers.

InterVenn’s AI-enabled mass spectrometry glycoproteomics platform enables researchers at academic centers and biopharmaceutical companies to assess post-translational modifications at an unprecedented scale and speed. The platform’s ability to process vast amounts of very complex data is, at long last, opening up glycoproteomics to clinical applications.

InterVenn further empowers researchers or biopharma firms to study biology and enhance drug development efforts using an omic dimension that closely recapitulates the disease phenotype.

Powered by large, human-curated datasets, InterVenn has developed advanced AI/ML algorithms to industrialize mass spectrometry, the only tool precise enough to measure the composition and location of Post-translational modifications (PTMs) at scale. The company’s first commercially available panel, VENN Vista, can assess blood (serum or plasma) protein glycosylation in a site-specific manner across more than 500 peptides and glycopeptides. Site-specific measurement of protein glycoforms provides unique insight into protein functionality that traditional immunoassays or aptamer-based approaches do not deliver. The firm has also built an open access online portal, OpenPIP, providing state-of-the-art neural networks for mass spectrometry peak integration.

InterVenn has developed GLORI, a first-in-class mass spec-based glycoproteomic clinical diagnostic test for ovarian cancer. This simple blood test will enable clinicians to distinguish benign and malignant masses in women with adnexal (pelvic) masses. Intervenn has also raised Series C financing from SoftBank Group, Heritage Provider Network, Irving Investors, and Highside Capital Management. The fund will predominantly be allocated for the development and commercialization of DAWN, a blood-based test aimed at helping physicians match cancer patients to immuno-oncology therapy with the best possible chance of response.

Aldo Carrascoso, the CEO and co-founder, seeks to revolutionize the fight against cancer through artificial intelligence (AI) and aims to launch products that could help cancer patients, doctors, and scientists. It’s a personal undertaking to Aldo, having lost his mother and two close relatives to breast cancer many years ago. Currently, the company has a wide range of breakthrough tests for various types of cancers and diseases in the pipeline. InterVenn’s non-traditional approach to epi-proteomics is a marriage of mass spectrometry and Artificial Intelligence / Machine Learning (AI/ML). The goal of InterVenn is to create a world where no one is blindsided by disease.